Natera’s president of medical diagnostics sells $809k in inventory

AUSTIN, Texas—Solomon Moshkevich, President of Medical Diagnostics at Natera, Inc. (NASDAQ:NTRA), just lately executed a big transaction involving the corporate’s inventory. Based on a Kind 4 submitting with the Securities and Trade Fee, Moshkevich offered 4,858 shares of Natera’s widespread inventory on December 9, 2024, at a weighted common value of $166.5937 per share. This sale amounted to a complete worth of roughly $809,312. The transaction comes as Natera’s inventory trades close to its 52-week excessive of $175.63, having delivered a formidable 185% return over the previous yr, in keeping with InvestingPro information.

Along with the sale, Moshkevich additionally acquired shares by the train of inventory choices. He acquired 5,752 shares at a value of $7.4491 per share and an extra 3,323 shares at $12.8501 per share. The whole worth of those acquisitions was $85,548. The sale of shares was a part of a technique to fulfill tax withholding obligations associated to the train of choices, in compliance with Rule 10b5-1.

Following these transactions, Moshkevich holds a complete of 114,912 shares of Natera’s widespread inventory.

In different current information, Natera Inc (NASDAQ:NTRA). reported document Q3 income of $439.8 million, a 64% improve year-over-year, and carried out 137,000 oncology assessments, marking a 54% improve from the earlier yr. The corporate’s gross margins reached a document excessive of 62%, resulting in a revision of its full-year income steering to between $1.61 billion and $1.64 billion. Natera’s Signatera check, a serious income contributor, confirmed promising leads to predicting survival and chemotherapy advantages in colorectal most cancers.

Within the backdrop of those sturdy monetary outcomes, analyst corporations TD Cowen, Baird, and Jefferies have maintained favorable scores on Natera’s inventory and raised their value targets. In different developments, Natera amended its settlement with Government Chairman Dr. Rabinowitz, who will proceed his position on an at-will foundation, with an annual base wage set at half of the corporate’s CEO’s base wage.

Nonetheless, Natera confronted a setback in a false promoting lawsuit towards Guardant Well being (NASDAQ:GH), however the firm stays agency in its disagreement with the choice. These are a number of the current developments shaping the trajectory of Natera Inc.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.